Clearside Biomedical Dividendos y recompras

Dividendo controles de criterios 0/6

Clearside Biomedical no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-216.5%

Rendimiento de la recompra

Rendimiento total para el accionista	-216.5%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Actualización de narrativa • Dec 15

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Artículo de análisis • Jun 24

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Artículo de análisis • Nov 12

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Artículo de análisis • Aug 11

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

The analysts covering Clearside Biomedical, Inc. ( NASDAQ:CLSD ) delivered a dose of negativity to shareholders today...

Seeking Alpha • Aug 08

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Seeking Alpha • Apr 13

Clearside Biomedical: A Pivotal 2022 Ahead

XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Partner Aura Biosciences will select the route of administration for lead drug candidate AU-011. Clearside is actively seeking gene therapy partners.

Seeking Alpha • Dec 22

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis. XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it. Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.

Artículo de análisis • Sep 30

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 07

Clearside's Value Proposition Is Far From Clear

Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value. Self-owned programs are in early stages and face stiff competition.

Artículo de análisis • Jun 17

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CLSD.Q han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CLSD.Q han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Clearside Biomedical vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de CLSD.Q con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (CLSD.Q)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Pharmaceuticals)	2.0%
Analista de previsiones (CLSD.Q) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CLSD.Q en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CLSD.Q en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de CLSD.Q para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CLSD.Q no ha comunicado ningún pago.

Descubre empresas que pagan buenos dividendos

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/06/08 19:06
Precio de las acciones al final del día	2026/06/05 00:00
Beneficios	2025/09/30
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Clearside Biomedical, Inc. está cubierta por 8 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Esther Lannie Hong	Brean Capital Historical (Janney Montgomery)
Debanjana Chatterjee	JonesTrading Institutional Services, LLC
Anupam Rama	J.P. Morgan

Clearside Biomedical Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

First Motion for Exclusivity Period Extension Approved For Clearside Biomedical, Inc.

Clearside Biomedical Files Form 15

CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside

Clearside Biomedical, Inc. To Be Delisted from Nasdaq

Clearside Biomedical, Inc. Receives Delisting Notice from Nasdaq

Clearside Biomedical, Inc. Filed for Bankruptcy

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc. Receives A Non-Compliance Notice from the Listing Qualifications Department of Nasdaq

Clearside Biomedical Receives Staff Determination Letter from Nasdaq Due to Failure to Regain Compliance with the Minimum Bid Price Requirement within the 180-Calendar Day Grace Period

Clearside Biomedical Announces Approval of XIPERE Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical, Inc. Announces Reduction in Force

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical Data Featured in Six Presentations At Association for Research in Vision and Ophthalmology 2025 Meeting

Clearside Biomedical, Inc. to Report Q1, 2025 Results on May 14, 2025

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc., Annual General Meeting, May 30, 2025

Clearside Biomedical, Inc.'s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical’S Asia-Pacific Partner, Arctic Vision, Announces Acceptance of Its New Drug Application for Arcatus® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

Clearside Biomedical Announces Additional Data from the Cls-Ax Oysysy Phase 2B Trial Presented At the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical, Inc. Announces Its Asia-Pacific Partner, Arctic Vision, Receives Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors